{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:15:51Z","timestamp":1792451751025,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The antibody\u2013drug conjugates (ADCs) sacituzumab govitecan (SG) and datopotamab deruxtecan target trophoblast cell surface antigen 2 (TROP-2) and have shown significant efficacy in HER2-negative metastatic breast cancer (mBC). As TROP-2 may serve as a target across multiple treatment lines, detailed information on TROP-2 expression over time is of great interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TROP-2 expression was analyzed in breast cancer (BC) samples from patients treated at the University Hospital W\u00fcrzburg between 2004 and 2025 at clinically indicated biopsy time points (TP), and, in a subset, before and after SG treatment. Expression was assessed immunohistochemically using the H-score (range 0\u2013300).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We evaluated 229 samples from 76 patients. Overall, patient-level TROP-2 expression was high (mean H-score 241.3\u2009\u00b1\u200973.2) and largely stable over time (TP1: 235.7\u2009\u00b1\u200960.8, n\u2009=\u200976; TP2: 244.6\u2009\u00b1\u200977.4, n\u2009=\u200972; TP3: 245.3\u2009\u00b1\u200984.4, n\u2009=\u200939; TP4: 244.9\u2009\u00b1\u200995.6, n\u2009=\u20098). However, 21 patients exhibited a decline in TROP-2 expression during disease progression, defined as a decrease of\u2009\u2265\u200950 H-score points between two consecutive TPs. Among 13 patients with paired biopsies obtained pre- and post-SG treatment, the mean TROP-2 H-score decreased from 227.0\u2009\u00b1\u200974.6 before SG to 202.9\u2009\u00b1\u200999.4 after SG (mean change\u2009\u2212\u200924.1\u2009\u00b1\u200986.0; median 1.7, range\u2009\u2212\u2009170 to 110; Wilcoxon p\u2009=\u20090.542). TROP-2 H-score decreased in 6\/13 patients and increased in 7\/13 patients. Exploratory PFS analysis showed no statistically significant difference by post-SG TROP-2 change (log-rank p\u2009=\u20090.526).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TROP-2 expression was generally high and relatively stable; however, some patients showed declining levels over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06551-4","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:44:47Z","timestamp":1784274287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer"],"prefix":"10.1007","volume":"152","author":[{"given":"M.","family":"Weich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Christl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kiesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"W\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Diessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gerhard-Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schlaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"1","key":"6551_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00341-6","volume":"7","author":"M Aslan","year":"2021","unstructured":"Aslan M et al (2021) Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer 7(1):141","journal-title":"NPJ Breast Cancer"},{"key":"6551_CR2","unstructured":"AstraZeneca 2024 Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial, Vol. 2025."},{"issue":"16","key":"6551_CR3","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A et al (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384(16):1529\u20131541","journal-title":"N Engl J Med"},{"issue":"19","key":"6551_CR4","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A et al (2024a) Datopotamab Deruxtecan in Advanced or Metastatic HR+\/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol 42(19):2281\u20132294","journal-title":"J Clin Oncol"},{"issue":"15","key":"6551_CR5","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A et al (2024b) Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol 42(15):1738\u20131744","journal-title":"J Clin Oncol"},{"issue":"3","key":"6551_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A et al (2025) Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol 43(3):285\u2013296","journal-title":"J Clin Oncol"},{"key":"6551_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.031","author":"RA Dent","year":"2025","unstructured":"Dent RA, Shao Z, Schmid P, Cort\u00e9s JC, Cescon DW, Saji S, Jung KH, Bachelot T, Wang S, Basaran G, Chae YS, Mathiba RM, Chen S-C, Stradella A, Battelli N, Niikura N, Zhao K, Vukovi\u0107 P, Maxwell MJ, Traina TA (2025) LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: primary results from the randomised, phase III TROPION-Breast02 trial. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.031","journal-title":"Ann Oncol"},{"issue":"1","key":"6551_CR8","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1186\/s12885-022-10076-7","volume":"22","author":"Y Jeon","year":"2022","unstructured":"Jeon Y et al (2022) Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. BMC Cancer 22(1):1014","journal-title":"BMC Cancer"},{"key":"6551_CR9","doi-asserted-by":"publisher","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, and AWMF) 2025 S3-Leitlinie \u201eDiagnostik, Therapie und Nachsorge maligner Ovarialtumoren\u201c: Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF: Langversion\u00a03.0, 2019, AWMF-Registernummer:\u00a0032\/035OL Forum 5 https:\/\/doi.org\/10.1007\/s12312-019-00671-4","DOI":"10.1007\/s12312-019-00671-4"},{"key":"6551_CR10","doi-asserted-by":"crossref","unstructured":"Marme, F.; Stickeler E., Furlanetto J. et al. 2021 Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. In ASCO Annual Meeting J Clin Oncol.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS602"},{"issue":"8 Suppl","key":"6551_CR11","first-page":"4244s","volume":"46","author":"KS McCarty Jr","year":"1986","unstructured":"McCarty KS Jr et al (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46(8 Suppl):4244s\u20134248s","journal-title":"Cancer Res"},{"issue":"3","key":"6551_CR12","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138\u2013140","journal-title":"Pathologe"},{"issue":"10411","key":"6551_CR13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402(10411):1423\u20131433","journal-title":"Lancet"},{"issue":"1","key":"6551_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-021-06390-6","volume":"191","author":"S Shiino","year":"2022","unstructured":"Shiino S et al (2022) Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. Breast Cancer Res Treat 191(1):1\u201314","journal-title":"Breast Cancer Res Treat"},{"issue":"3\u20134","key":"6551_CR15","first-page":"84","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B (2015) Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer 6(3\u20134):84\u2013105","journal-title":"Genes Cancer"},{"key":"6551_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-018-4954-7","author":"TN Stueber","year":"2018","unstructured":"Stueber TN et al (2018) Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer. Arch Gynecol Obstet. https:\/\/doi.org\/10.1007\/s00404-018-4954-7","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"6551_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM et al (2026) Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med 394(4):354\u2013366","journal-title":"N Engl J Med"},{"issue":"11","key":"6551_CR18","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC et al (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 142(11):1364\u20131382","journal-title":"Arch Pathol Lab Med"},{"issue":"22","key":"6551_CR19","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC et al (2023) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol 41(22):3867\u20133872","journal-title":"J Clin Oncol"},{"key":"6551_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117863","volume":"296","author":"X Zhang","year":"2025","unstructured":"Zhang X et al (2025) Evolution of TROP2: Biological insights and clinical applications. Eur J Med Chem 296:117863","journal-title":"Eur J Med Chem"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06551-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:20:51Z","timestamp":1784283651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06551-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["6551"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06551-4","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study design and protocol were reviewed and approved by the Ethics Committee of the University of W\u00fcrzburg (approval number 2023012301) on March 8, 2023. Informed consent was not required due to anonymized material and the lack of images that may identify an individual person.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author TS received speaker honoraria and travel support from Gilead Sciences GmbH. All other authors declare they have no financial interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"142"}}